Cost-Effectiveness Analysis of Crizanlizumab in Sickle Cell Disease in Iran

Background: Sickle cell disease (SCD) prevalence is predicted to rise dramatically in the upcoming years. Although several medications have received Food and Drug Administration (FDA) approval in recent years, low- and middle-income countries (LMICs) still struggle to access these medications due to...

Full description

Saved in:
Bibliographic Details
Main Authors: Marzieh Nosrati, Shadi Izadidehkordi, Shekoufeh Nikfar, Fatemeh Sadat Heydari
Format: Article
Language:English
Published: Shiraz University of Medical Sciences 2025-08-01
Series:Iranian Journal of Medical Sciences
Subjects:
Online Access:https://ijms.sums.ac.ir/article_51078_3ed130f6ad6d84cd2a423316653e315f.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!